Clinigen Group PLC
LSE:CLIN
Intrinsic Value
Clinigen Group Plc engages in the provision of pharmaceutical products and services. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CLIN.
Clinigen Group PLC's market capitalization is 1.2B GBX.
CLIN stock price is 925 GBX.
CLIN.
CLIN. Open DCF Valuation
CLIN. Open Relative Valuation
CLIN has downside potential of 11% compared to the average analyst price target.
Open Wall St Estimates
CLIN's ROIC (Return on Invested Capital) has decreased in the last 3 years from 7% to 7%.
CLIN's ROE (Return on Equity) has increased in the last 3 years from 7% to 8%.
CLIN's ROE (Return on Equity) for the past 12 months is positive and is equal to 8%.
CLIN has positive Operating Income for the last twelve months.
CLIN's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
CLIN's Altman Z-Score is equal to 2.59.
CLIN's Revenue has grown by 14% over the past 12 months.
CLIN's D/E (Debt to Equity) is very low and is equal to 0.9.
CLIN has positive Net Income for the last twelve months.
CLIN has positive three-year average ROE (Return on Equity): 6%. The company is efficient at transforming stockholders' equity into net income.
CLIN has positive three-year average ROIC (Return on Invested Capital): 6%. The company is efficient at using invested capital to generate operating income.
CLIN has positive Free Cash Flow for the last twelve months.
CLIN's long-term assets (1B GBP) exceed its long-term liabilties (594m GBP).
CLIN's short-term assets (295m GBP) exceed its short-term liabilties (157m GBP).
CLIN has positive Gross Profit for the last twelve months.
CLIN has positive Net Debt. This means that the company has more debt (409m GBP) than cash and short-term investments (118m GBP).
CLIN generates enough operating income (85m GBP) to cover interest payments on its debt (11m GBP).
Fundamental Analysis
Clinigen Group PLC
Balance Sheet Decomposition
Clinigen Group PLC
| Current Assets | 295.4m |
| Cash & Short-Term Investments | 117.5m |
| Receivables | 114.8m |
| Other Current Assets | 63.1m |
| Non-Current Assets | 753.2m |
| Long-Term Investments | 1.2m |
| PP&E | 39.6m |
| Intangibles | 330.4m |
| Other Non-Current Assets | 382m |
| Current Liabilities | 156.5m |
| Other Current Liabilities | 156.5m |
| Non-Current Liabilities | 437m |
| Long-Term Debt | 408.8m |
| Other Non-Current Liabilities | 28.2m |
Earnings Waterfall
Clinigen Group PLC
|
Revenue
|
807.5m
GBP
|
|
Cost of Revenue
|
-509.2m
GBP
|
|
Gross Profit
|
298.3m
GBP
|
|
Operating Expenses
|
-212.9m
GBP
|
|
Operating Income
|
85.4m
GBP
|
|
Other Expenses
|
-47.9m
GBP
|
|
Net Income
|
37.5m
GBP
|
Free Cash Flow Analysis
Clinigen Group PLC
CLIN Profitability Score
Profitability Due Diligence
Clinigen Group PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Clinigen Group PLC's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
CLIN Solvency Score
Solvency Due Diligence
Clinigen Group PLC's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Clinigen Group PLC's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLIN Price Targets Summary
Clinigen Group PLC
According to Wall Street analysts, the average 1-year price target for
CLIN
is 821.8 GBX
.
Shareholder Return
CLIN Price
Clinigen Group PLC
| Average Annual Return | -14.84% |
| Standard Deviation of Annual Returns | 13.28% |
| Max Drawdown | -67% |
| Market Capitalization | 1.2B GBX |
| Shares Outstanding | 133 367 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Clinigen Group PLC
Country
Industry
Market Cap
Dividend Yield
Description
Clinigen Group Plc engages in the provision of pharmaceutical products and services. The company is headquartered in Burton Upon Trent, Staffordshire and currently employs 1,013 full-time employees. The company went IPO on 2012-09-25. The firm's principal activities are focused on providing healthcare professionals (HCPs) and their patients with access to medicines. The company operates through two segments: Services and Products. Its product brands include ACETYLCYSTEINE, COLECALCIFEROL, CARDIOXANE, ERWINASE / ERWINAZE, ETHYOL, FOLIC ACID COLONIS, FOSCAVIR, GABAPENTIN COLONIS, GLYCOPYRRONIUM BROMIDE, ILOPROST, IMUKIN / IMMUKIN / IMMUKINE, METFORMIN COLONIS, NORTRIPTYLINE COLONIS, PROLEUKIN and SAVENE, among others. The services provided by the Company includes clinical supplies management, managed access programs, real world data and medical science liaison (MSL). The company operates in locations across North America, Europe, Africa, Japan and Asia Pacific. Its subsidiaries include Clinigen Healthcare B.V., Clinigen Clinical Trials Limited, Link Healthcare Singapore Pte. Limited and Clinigen South Africa (Pty) Limited, among others.
You don't have any saved screeners yet
